A discussion with the presidents of the Association of Cancer Care Centers (ACCC) and the American Society of Clinical Oncology took place at the ACCC 51st Annual Meeting & Cancer Center Business Summit.

Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2.

This is the fourth article in a series on value-based care and the four challenges health care organizations must overcome.

A letter from the guest editor highlights how the findings in this special issue touch on timely themes in health technology research and yield real-world considerations for practice.

The American College of Gastroenterology warns millions may lose access to life-saving colorectal cancer screenings.

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to severe psoriasis across 2 studies.

Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.

Physicians are more likely to order respiratory pathogen testing since the COVID-19 pandemic, affecting testing rates and costs.

Here are key facts, risk factors, and life-saving screening recommendations for colorectal cancer prevention and treatment.

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

This article explores the challenges and highlights actionable telehealth solutions that enhance access to care, particularly for mothers at higher risk of postpartum depression.

A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Nick Webb tells attendees at the Association of Cancer Care Centers that consumer experience and workforce happiness will be keys to success in the future for health systems.

This systematic literature review and pooled rates analysis investigated the standard of care for patients with heart failure in the US post hospital discharge.

This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention and treatment of viral infections like HIV and COVID-19.

Telemedicine utilization has declined since the peak of the COVID-19 pandemic, but non–primary care specialties continue to see an increase in moderate- and high-complexity telemedicine visits.

Information on health equity was removed by the federal government for both the Children’s Health Insurance Program and Medicaid.

Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.

Artificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while improving clinical and equity outcomes.

A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

Posters presented at the Association of Cancer Care Centers (ACCC) opening session covered initiatives to boost clinical trial diversity and address disparities in bladder cancer trials.

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

Jay Bhattacharya, MD, PhD, defended his vision for the National Institutes of Health in a Senate committee confirmation hearing, tackling concerns on research funding, public trust, and scientific integrity.